Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Subcutaneous Doses of Cagrilintide in Chinese Men
NCT05254158Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cagrilintide in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity. Started Mar 2022; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05254158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254158.